A government crackdown on foreign investment has sent speculators fleeing, but one man is more bullish than ever
The key is the search giant’s “launch and iterate” approach to new products, which uses early user feedback to make adjustments
The Canadian government is fast-tracking visas for skilled tradesmen like plumbers and electricians
It's not enough to offer ratings and reviews anymore—the best review data are what people actually bought
Once mom and pop operations, some have billions in assets
Simple tablets manufactured by such "local brands" as Eben, Micromax, and Texet are expected to account of one-fourth of global sales this year
J.J. Abrams's Star Trek Into Darkness debuted at No. 1—yet it was a lackluster first-place showing
Looking for ethics? Set your GPS to Notre Dame or BYU
Quit-smoking apps get hot in a $1 billion market
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.